Method of reducing cholesterol levels using a human anti-PCSK9 antibody
US-9561155-B2 · Feb 7, 2017 · US
Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9920134B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9920134-B2 |
| Application number | US-201113174423-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 30, 2011 |
| Priority date | Aug 23, 2007 |
| Publication date | Mar 20, 2018 |
| Grant date | Mar 20, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
First claim
Opening claim text (preview).
What is claimed is: 1. A monoclonal antibody that binds to a PCSK9 protein, wherein the PCSK9 protein comprises the amino acid sequence of SEQ ID NO: 1, wherein the monoclonal antibody comprises a light chain complementarity determining region (CDR) CDR 1 that is a CDR1 in SEQ ID NO:46; a light chain CDR2 that is a CDR2 in SEQ ID NO:46; and a light chain CDR3 that is a CDR3 in SEQ ID NO: 46, and wherein the monoclonal antibody comprises a heavy chain CDR1 that is a CDR1 in SEQ ID…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9920134B2 cover?
- Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
- Who is the assignee on this patent?
- Jackson Simon Mark, Walker Nigel Pelham Clinton, Piper Derek Evan, and 9 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/395. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).